相似文献
1
Rifampin and rifabutin resistance mechanism in Helicobacter pylori.
Antimicrob Agents Chemother. 1999 Jun;43(6):1497-9. doi: 10.1128/AAC.43.6.1497.
2
Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany.
J Antimicrob Chemother. 2007 May;59(5):874-9. doi: 10.1093/jac/dkm039. Epub 2007 Mar 9.
3
Molecular characterization of Helicobacter pylori resistance to rifamycins.
Helicobacter. 2018 Feb;23(1). doi: 10.1111/hel.12451. Epub 2017 Nov 23.
4
Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori.
Digestion. 2009;79(1):1-4. doi: 10.1159/000191204. Epub 2009 Jan 14.
5
Molecular characterization of rifabutin-resistance in refractory Helicobacter pylori infection in Taiwan.
Int J Infect Dis. 2024 Jan;138:25-28. doi: 10.1016/j.ijid.2023.11.001. Epub 2023 Nov 11.
6
Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2000 Apr;44(4):1075-7. doi: 10.1128/AAC.44.4.1075-1077.2000.
7
In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
Clin Microbiol Infect. 2004 Jul;10(7):662-5. doi: 10.1111/j.1469-0691.2004.00917.x.
8
Acquisition of rifabutin resistance by a rifampicin resistant mutant of Mycobacterium tuberculosis involves an unusual spectrum of mutations and elevated frequency.
Ann Clin Microbiol Antimicrob. 2005 Jun 15;4:9. doi: 10.1186/1476-0711-4-9.
9
Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.
J Antimicrob Chemother. 1998 Nov;42(5):621-8. doi: 10.1093/jac/42.5.621.
10
[Cross-resistance between rifampin and rifabutin in multidrug resistant Mycobacterium tuberculosis complex strains].
Zhonghua Jie He He Hu Xi Za Zhi. 2012 May;35(5):333-5.
引用本文的文献
1
Antibiotic resistance in Helicobacter pylori: a genetic and physiological perspective.
Gut Pathog. 2025 May 23;17(1):35. doi: 10.1186/s13099-025-00704-5.
2
Prevalence and antimicrobial resistance of highly virulent cagA-positive Helicobacter pylori strains in Southern Poland.
Eur J Clin Microbiol Infect Dis. 2025 Feb;44(2):405-416. doi: 10.1007/s10096-024-05018-z. Epub 2024 Dec 17.
3
Change in Diagnosis of Infection in the Treatment-Failure Era.
Antibiotics (Basel). 2024 Apr 12;13(4):357. doi: 10.3390/antibiotics13040357.
4
Antibiotic Resistance of : Mechanisms and Clinical Implications.
J Korean Med Sci. 2024 Jan 29;39(4):e44. doi: 10.3346/jkms.2024.39.e44.
5
Exploring Alternative Treatment Choices for Multidrug-Resistant Clinical Strains of in Mongolia.
Microorganisms. 2023 Nov 24;11(12):2852. doi: 10.3390/microorganisms11122852.
6
Whole Genome Sequencing for Studying Antimicrobial Resistance.
Antibiotics (Basel). 2023 Jun 30;12(7):1135. doi: 10.3390/antibiotics12071135.
7
Antibiotic resistance in Helicobacter pylori: From potential biomolecular mechanisms to clinical practice.
J Clin Lab Anal. 2023 Apr;37(7):e24885. doi: 10.1002/jcla.24885. Epub 2023 Apr 23.
8
Clinical Implication of Drug Resistance for Management.
Antibiotics (Basel). 2022 Nov 23;11(12):1684. doi: 10.3390/antibiotics11121684.
9
Rifabutin as salvage therapy for eradication: Cornerstones and novelties.
World J Gastroenterol. 2022 Dec 7;28(45):6356-6362. doi: 10.3748/wjg.v28.i45.6356.
10
Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.
Helicobacter. 2022 Aug;27(4):e12900. doi: 10.1111/hel.12900. Epub 2022 May 29.
本文引用的文献
1
Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7. doi: 10.1128/AAC.42.7.1853.
2
Detection of point mutations in rpoB gene of rifampin-resistant Rickettsia typhi.
Antimicrob Agents Chemother. 1998 Jul;42(7):1845-6. doi: 10.1128/AAC.42.7.1845.
3
Treatment of antibiotic-resistant Helicobacter pylori.
N Engl J Med. 1998 Jul 2;339(1):53. doi: 10.1056/NEJM199807023390116.
4
Molecular evolution of rifampicin resistance in Streptococcus pneumoniae.
Microb Drug Resist. 1998 Spring;4(1):65-70. doi: 10.1089/mdr.1998.4.65.
5
The complete genome sequence of the gastric pathogen Helicobacter pylori.
Nature. 1997 Aug 7;388(6642):539-47. doi: 10.1038/41483.
6
Rifampicin resistance in Neisseria meningitidis: evidence from a study of sibling strains, description of new mutations and notes on population genetics.
J Antimicrob Chemother. 1997 Jun;39(6):747-55. doi: 10.1093/jac/39.6.747.
7
A mechanism of rifamycin inhibition and resistance in Pseudomonas aeruginosa.
J Antimicrob Chemother. 1996 Jul;38(1):133-7. doi: 10.1093/jac/38.1.133.
8
Rifampin resistance in Neisseria meningitidis due to alterations in membrane permeability.
Antimicrob Agents Chemother. 1996 Mar;40(3):646-51. doi: 10.1128/AAC.40.3.646.
9
Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan.
Antimicrob Agents Chemother. 1996 Apr;40(4):1053-6. doi: 10.1128/AAC.40.4.1053.
10
Antimicrobial activity of rifabutin.
Clin Infect Dis. 1996 Apr;22 Suppl 1:S3-13; discussion S13-4. doi: 10.1093/clinids/22.supplement_1.s3.
Zotero 插件